CYP2D6 genotype and outcome in tamoxifen treated early breast cancer
DOI:
https://doi.org/10.2340/1651-226X.2025.43208Keywords:
CYP2D6, tamoxifen, breast cancer, adjuvant therapy, bioactivation, menopausal status, pharmacogeneticsAbstract
Background and purpose: The clinical significance of individual CYP2D6 activity for the outcome of tamoxifen treatment in early breast cancer is unclear. Our previous investigation in patients diagnosed over the period 1998–2000 indicated an association between reduced CYP2D6 activity and poor outcome in premenopausal women. The aim of this study was to investigate the association between CYP2D6 genotype and clinical outcome in a larger tamoxifen treated cohort.
Patients/material and methods: Swedish breast cancer patients who initiated adjuvant tamoxifen treatment over the period 2006–2014 constituted the full study cohort. Clinical information was collected from medical records. Data on endocrine treatment, use of CYP2D6 inhibitors was retrieved from the Swedish Prescribed Drug Register. CYP2D6 was genotyped and translated into predicted metabolic activity. The association between CYP2D6 activity and clinical outcome was analyzed using Cox regression, controlling for potential confounding variables. Subgroup analyses were performed based on menopausal status, tamoxifen treatment for at least 1 year and as single endocrine treatment, HER2-status and tamoxifen monotherapy.
Results: A total of 1,103 patients were included. A total of 761 patients received tamoxifen as monotherapy. A total of 42% were premenopausal. Median follow-up was 11.4 years. No significant association was found between CYP2D6 activity and recurrence (adjusted hazard ratio [aHR] 1.18, 95% CI 0.92; 1.52) or breast cancer mortality (aHR 1.41, 95%CI 0.93; 2.13) in the full cohort, or in the subgroup with tamoxifen monotherapy (aHR 1.39, CI 0.99; 1.96 and 1.88, CI 0.98; 3.60 respectively).
Interpretation: No association was noted between reduced CYP2D6 activity and poorer outcome in this early breast cancer cohort, with patients generally at lower risk of recurrence, reflecting the role of adjuvant tamoxifen in current clinical practice.
Downloads
References
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
https://doi.org/10.1016/S0140-6736(05)66544-0 DOI: https://doi.org/10.1016/S0140-6736(05)66544-0
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. . DOI: https://doi.org/10.1016/S0140-6736(12)61963-1
https://doi.org/10.1016/S0140-6736(17)31004-8 DOI: https://doi.org/10.1016/S0140-6736(17)31004-8
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46. PMID: 29117498.
https://doi.org/10.1056/NEJMoa1701830 DOI: https://doi.org/10.1056/NEJMoa1701830
He W, Grassmann F, Eriksson M, Eliasson E, Margolin S, Thorén L, et al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J Clin Oncol. 2020;38(6):548–57.
https://doi.org/10.1200/JCO.19.01535 DOI: https://doi.org/10.1200/JCO.19.01535
Mulder TAM, De With M, Del Re M, Danesi R, Mathijssen RHJ, Van Schaik RHN. Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER-positive breast cancer patients: current status of a controversy. Cancers (Basel). 2021;13(4):771.
https://doi.org/10.3390/cancers13040771 DOI: https://doi.org/10.3390/cancers13040771
Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8):1287–93.
https://doi.org/10.1200/JCO.2009.25.7246 DOI: https://doi.org/10.1200/JCO.2009.25.7246
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429–36.
https://doi.org/10.1001/jama.2009.1420 DOI: https://doi.org/10.1001/jama.2009.1420
Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013;19(2):500–7.
https://doi.org/10.1158/1078-0432.CCR-12-2153 DOI: https://doi.org/10.1158/1078-0432.CCR-12-2153
Margolin S, Lindh JD, Thoren L, Xie H, Koukel L, Dahl ML, et al. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics. 2013;14(6):613–22.
https://doi.org/10.2217/pgs.13.47 DOI: https://doi.org/10.2217/pgs.13.47
Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15(1):84–94.
https://doi.org/10.1038/tpj.2014.34 DOI: https://doi.org/10.1038/tpj.2014.34
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst. 2012;104(6):441–51.
https://doi.org/10.1093/jnci/djs125 DOI: https://doi.org/10.1093/jnci/djs125
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452–60. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.
https://doi.org/10.1093/jnci/djs126 DOI: https://doi.org/10.1093/jnci/djs126
Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014;95(2):216–27.
https://doi.org/10.1038/clpt.2013.186 DOI: https://doi.org/10.1038/clpt.2013.186
Chan CWH, Li C, Xiao EJ, Li M, Phiri PGM, Yan T, et al. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Exp Rev Mol Med. 2022;24:e1.
https://doi.org/10.1017/erm.2021.28 DOI: https://doi.org/10.1017/erm.2021.28
Sanchez-Spitman A DV, Swen J, Moes DJAR, Böhringer S, Batman E, Van Druten E, et al. Tamoxifen pharmacogenetics and metabolism: Results from the prospective CYPTAM study. J Clin Oncol. 2019;37(8):636–46.
https://doi.org/10.1200/JCO.18.00307 DOI: https://doi.org/10.1200/JCO.18.00307
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.
https://doi.org/10.1007/s10549-010-1132-4 DOI: https://doi.org/10.1007/s10549-010-1132-4
McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763–8.
https://doi.org/10.1038/sj.bjc.6604758 DOI: https://doi.org/10.1038/sj.bjc.6604758
Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515–24.
https://doi.org/10.1038/bjc.2013.116 DOI: https://doi.org/10.1038/bjc.2013.116
Font R, Espinas JA, Barnadas A, Izquierdo A, Galceran J, Saladie F, et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast Cancer Res Treat. 2019;175(3):733–40.
https://doi.org/10.1007/s10549-019-05201-3 DOI: https://doi.org/10.1007/s10549-019-05201-3
Binkhorst L, Mathijssen RH, Jager A, Van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015;41(3):289–99.
https://doi.org/10.1016/j.ctrv.2015.01.002 DOI: https://doi.org/10.1016/j.ctrv.2015.01.002
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–9.
https://doi.org/10.1093/jnci/dji005 DOI: https://doi.org/10.1093/jnci/dji005
NKCB [Internet]. [cited 2023 Jul 10]. Available form: https://statistik.incanet.se/brostcancer/
Thoren L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, et al. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. Br J Clin Pharmacol. 2021;87(3):1243–52.
https://doi.org/10.1111/bcp.14500 DOI: https://doi.org/10.1111/bcp.14500
Thorén L, Eriksson M, Lindh JD, Czene K, Bergh J, Eliasson E, et al. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. Breast Cancer Rese Treat. 2021;190(3):451–62.
https://doi.org/10.1007/s10549-021-06386-2 DOI: https://doi.org/10.1007/s10549-021-06386-2
Thoren L, Margolin S, Eliasson E, Bergh J, Lindh JD. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records. Breast Cancer Res Treat. 2023;198:499–508.
https://doi.org/10.1007/s10549-023-06887-2 DOI: https://doi.org/10.1007/s10549-023-06887-2
Goetz MP, Suman VJ, Nakamura Y, Kiyotani K, Jordan VC, Ingle JN. Tamoxifen metabolism and breast cancer recurrence: a question unanswered by CYPTAM. J Clin Oncolgy. 2019;37(22):1982–3.
https://doi.org/10.1200/JCO.19.00504 DOI: https://doi.org/10.1200/JCO.19.00504
National Prescribed Drug Register [Internet]. [cited 2023 Jun 15]. Available from: https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-prescribed-drug-register/
Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res. 2010;16(17):4468–77.
https://doi.org/10.1158/1078-0432.CCR-10-0478 DOI: https://doi.org/10.1158/1078-0432.CCR-10-0478
Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2019;13(1):116–24.
https://doi.org/10.1111/cts.12692 DOI: https://doi.org/10.1111/cts.12692
Molden E, Jukic MM. CYP2D6 reduced function variants and genotype/phenotype translations of CYP2D6 intermediate metabolizers: implications for personalized drug dosing in psychiatry. Front Pharmacol. 2021;12:650750.
https://doi.org/10.3389/fphar.2021.650750 DOI: https://doi.org/10.3389/fphar.2021.650750
Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21.
https://doi.org/10.1097/MLR.0b013e31829b1d2a DOI: https://doi.org/10.1097/MLR.0b013e31829b1d2a
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(8): DOI: https://doi.org/10.1093/annonc/mdz173
1194–220.
https://doi.org/10.1016/j.annonc.2020.08.2158. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1674.https://doi.org/10.1093/annonc/mdz189. Erratum in: Ann Oncol. 2021 Feb;32(2):284. DOI: https://doi.org/10.1093/annonc/mdz189
https://doi.org/10.1016/j.annonc.2020.08.2158. DOI: https://doi.org/10.1016/j.annonc.2020.08.2158
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–46.
https://doi.org/10.1093/annonc/mdv221 DOI: https://doi.org/10.1093/annonc/mdv221
Early Breast Cancer Trialists’ Collaborative Group (EBCTC). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1997;351(9114):1451–67.
https://doi.org/10.1016/S0140-6736(97)11423-4 DOI: https://doi.org/10.1016/S0140-6736(97)11423-4
Almeida T SW, Nardin J, Mürdter TE, Winter S, Picolotto S, Hoppe R, et al. (Z)-endoxifen and early recurrence of breast cancer: an explorative analysis in a prospective Brazilian study. J Pers Med. 2022;12(4):511.
https://doi.org/10.3390/jpm12040511 DOI: https://doi.org/10.3390/jpm12040511
Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B, et al. Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol. 2017;8:582.
https://doi.org/10.3389/fphar.2017.00582 DOI: https://doi.org/10.3389/fphar.2017.00582
Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, et al. Factors affecting tamoxifen metabolism in patients with breast cancer: preliminary results of the French PHACS study. Clin Pharmacol Ther. 2019;106(3):585–95.
https://doi.org/10.1002/cpt.1404 DOI: https://doi.org/10.1002/cpt.1404
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Therap. 2011;89(5):718–25.
https://doi.org/10.1038/clpt.2011.32 DOI: https://doi.org/10.1038/clpt.2011.32
Hammarström MGM, Bergqvist J, Lundholm C, Crippa A, Bäcklund M, Wengström Y, et al. Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial. J Natl Cancer Inst. 2025;117(4):629–36.
https://doi.org/10.1093/jnci/djae280 DOI: https://doi.org/10.1093/jnci/djae280
Statistik Bröstcancer: Cancerfonden [Internet]. 2021 [cited 2023 Mar 15]. Available from: https://www.cancerfonden.se/om-cancer/statistik/brostcancer
NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.2 (23.06.2022) [Internet]. Association of the Nordic Cancer Registries. Cancer Registry of Norway. [cited 2023 Jul 20]. Available from: https://nordcan.iarc.fr/
Loibl SAF, Bachelot T, Barrios CH, Bergh J, Burstein HJ et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up ☆. Ann Oncol. 2024;35(2):159–82.
https://doi.org/10.1016/j.annonc.2023.11.016 DOI: https://doi.org/10.1016/j.annonc.2023.11.016
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.
https://doi.org/10.1016/S0140-6736(15)61074-1 DOI: https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.
https://doi.org/10.1016/S0140-6736(11)61625-5 DOI: https://doi.org/10.1016/S0140-6736(11)61625-5
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100000 women from 86 randomised trials. Lancet. 2023;401(10384):1277–92.
https://doi.org/10.1016/S0140-6736(23)00285-4 DOI: https://doi.org/10.1016/S0140-6736(23)00285-4
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139–50.
https://doi.org/10.1016/S1470-2045(21)00288-6 DOI: https://doi.org/10.1016/S1470-2045(21)00288-6
Lenk HÇ, Klöditz K, Johansson I, Smith RL, Jukić MM, Molden E, et al. The polymorphic nuclear factor NFIB regulates hepatic CYP2D6 expression and influences risperidone metabolism in psychiatric patients. Clin Pharmacol Ther. 2022;111(5):1165–74.
https://doi.org/10.1002/cpt.2571 DOI: https://doi.org/10.1002/cpt.2571
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Linda Thorén, Jonatan D. Lindh, Espen Molden, Marianne Kristiansen Kringen, Jonas Bergh, Erik Eliasson, Sara Margolin
This work is licensed under a Creative Commons Attribution 4.0 International License.
